Core Viewpoint - AskGene Pharma has entered into a licensing agreement with Visara, allowing Visara to commercialize the innovative drug project ASK712, which targets both VEGF and ANG-2 for the treatment of retinal diseases [1][2] Group 1: Licensing Agreement - The licensing agreement enables the development and commercialization of the ASK712 project in the licensed area, which is expected to positively impact the company's future performance [2] - This agreement aligns with the company's strategic focus on innovative drug development in areas such as digestion, oncology, anti-infection, and chronic diseases [2] Group 2: Drug Development - ASK712 is a first-class innovative drug developed by AskGene Pharma, currently in the IIa clinical research phase in China [1] - Clinical results from the I phase show that ASK712 has good safety and efficacy, with preclinical data indicating stronger binding activity to VEGF and ANG-2 compared to existing treatments [1]

Core Viewpoint - AskGene Pharma has entered into a licensing agreement with Visara for its innovative drug project ASK712, which targets both VEGF and ANG-2, indicating a strategic move towards enhancing its research and commercialization efforts in the therapeutic area of eye diseases [1][2] Group 1: Licensing Agreement - AskGene Pharma has licensed its proprietary rights for the innovative drug ASK712 to Visara, which is expected to facilitate the development and commercialization of the drug in the licensed area [1] - The licensing agreement aligns with the company's strategic focus on innovation in drug development, particularly in areas such as digestion, oncology, anti-infection, and chronic diseases [2] Group 2: Drug Development and Clinical Trials - ASK712 is currently in the Phase IIa clinical trial stage in China, demonstrating good safety and efficacy based on Phase I dose escalation and expansion results [1] - Preclinical data suggests that ASK712 has a stronger binding affinity for VEGF and ANG-2 compared to existing treatments, potentially improving efficacy and extending dosing intervals, which may enhance patient compliance [1]

Core Viewpoint - Aosaikang (SZ 002755) announced the convening of its seventh fourth board meeting on October 15, 2025, to review documents including the proposal for signing an authorization agreement [1] Company Summary - Aosaikang's revenue composition for the year 2024 is as follows: 97.92% from the pharmaceutical manufacturing industry and 2.08% from other businesses [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 证券代码：002755 证券简称：奥赛康 公告编号：2025-052 北京奥赛康药业股份有限公司 关于签署授权许可协议的公告 北京奥赛康药业股份有限公司（以下简称"公司"）的控股子公司 AskGene Pharma, Inc.（以下简称"AskGene Pharma"）与 Visara, Inc.（以下简称"Visara"） 达成授权许可协议，将 AskGene Pharma 具有自主知识产权的 1 类创新药 ASKG712 项目在许可区域内的权益有偿许可给 Visara。 被许可方：Visara, Inc. 本次交易已经公司第七届董事会第四次会议审议通过。本次交易不构成关联 交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 二、许可项目基本信息 ASKG712 是 AskGene Pharma 自主研发的、拥有自主知识产权的 1 类创新药， 可同时靶向 VEGF 与 ANG-2。在阻断 VEGF/VEGFR 信号通路，控制新生血管形 成的同时，可有效抑制 ANG-2 信号以改善血管 ...

证券代码：002755 证券简称：奥赛康 公告编号：2025-051 表决结果：9 票同意，0 票反对，0 票弃权。 同意公司的控股子公司 AskGene Pharma, Inc.（以下简称"AskGene Pharma"） 与 Visara, Inc.（以下简称"Visara"）签署授权许可协议，将 AskGene Pharma 具有 自主知识产权的 1 类创新药 ASKG712 项目在许可区域内的权益有偿许可给 Visara。 具体内容详见同日发布于巨潮资讯网（http://www.cninfo.com.cn）上的《关 于签署授权许可协议的公告》（公告编号：2025-052）。 备查文件 《公司第七届董事会第四次会议决议》 特此公告。 北京奥赛康药业股份有限公司 第七届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）第七届董事会第四次会议 于 2025 年 10 月 11 日以书面发送、专人送达的方式通知各位董事，会议于 2025 年 10 月 15 日以现场会议的方式在南京江宁科学园 ...

Core Insights - The stock price of Aosaikang increased by 2.01% on October 15, reaching 19.30 CNY per share, with a total market capitalization of 17.913 billion CNY [1] - Aosaikang's stock has seen a year-to-date increase of 53.30%, but has experienced declines of 6.90% over the last five trading days, 12.75% over the last twenty days, and 10.90% over the last sixty days [1] - The company reported a revenue of 1.007 billion CNY for the first half of 2025, reflecting a year-on-year growth of 9.20%, and a net profit of 160 million CNY, which is a significant increase of 111.64% [2] Company Overview - Aosaikang Pharmaceutical Co., Ltd. was established on December 24, 1996, and went public on May 15, 2015. The company is located in Jiangning Science Park, Nanjing, Jiangsu Province [1] - The main business areas include research, production, and sales of drugs, with revenue composition as follows: oncology drugs 38.28%, anti-infection drugs 24.74%, chronic disease drugs 21.65%, digestive drugs 12.33%, and others 2.34% [1] Shareholder and Dividend Information - As of September 20, 2025, the number of shareholders increased by 2.46% to 20,000, while the average number of circulating shares per person decreased by 2.40% to 46,298 shares [2] - Aosaikang has distributed a total of 721 million CNY in dividends since its A-share listing, with 111 million CNY distributed in the last three years [3] - Notable institutional shareholders include Yongying Medical Innovation Mixed Fund, which is a new shareholder holding 11.686 million shares, and Hong Kong Central Clearing Limited, also a new shareholder with 4.687 million shares [3]

10月13日，奥赛康盘中下跌2.00%，截至10:16，报19.58元/股，成交9574.68万元，换手率0.52%，总市 值181.73亿元。 资金流向方面，主力资金净流出998.88万元，特大单买入285.59万元，占比2.98%，卖出654.68万元，占 比6.84%；大单买入971.32万元，占比10.14%，卖出1601.11万元，占比16.72%。 奥赛康今年以来股价涨55.52%，近5个交易日跌6.54%，近20日跌14.83%，近60日涨0.72%。 今年以来奥赛康已经2次登上龙虎榜，最近一次登上龙虎榜为7月16日。 资料显示，北京奥赛康药业股份有限公司位于江苏省南京市江宁科学园科建路699号，成立日期1996年 12月24日，上市日期2015年5月15日，公司主营业务涉及消化类、抗肿瘤类及其他药品的研发、生产和 销售。主营业务收入构成为：抗肿瘤类38.28%，抗感染类24.74%，慢性病类21.65%，消化类12.33%， 其他(补充)2.34%，其他类0.66%。 奥赛康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：医药电商、幽门螺杆概 念、生物医药、创新药、抗癌治癌等。 ...

Core Viewpoint - As of September 30, 2023, Aosaikang's stock price increased by 2.03% to 20.57 CNY per share, with a market capitalization of 19.092 billion CNY, despite a net outflow of main funds amounting to 14.2823 million CNY [1] Group 1: Stock Performance - Aosaikang's stock has risen by 63.38% year-to-date, but has seen a decline of 1.20% over the last five trading days and 11.83% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 16 [1] Group 2: Financial Performance - For the first half of 2025, Aosaikang reported a revenue of 1.007 billion CNY, representing a year-on-year growth of 9.20%, and a net profit attributable to shareholders of 160 million CNY, which is a significant increase of 111.64% [2] - Cumulatively, Aosaikang has distributed 721 million CNY in dividends since its A-share listing, with 111 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of September 20, 2023, Aosaikang had 20,000 shareholders, an increase of 2.46% from the previous period, with an average of 46,298 circulating shares per shareholder, down by 2.40% [2] - Notable changes in institutional holdings include the entry of Yongying Medical Innovation Mixed Fund as the sixth largest shareholder, holding 11.6856 million shares, and the exit of several funds from the top ten shareholders list [3]

Core Viewpoint - The global plant alkaloid market is experiencing stable growth, with projections indicating an increase from $8.72 billion in 2015 to $14.49 billion in 2024, and further to $15.94 billion by 2025. The Chinese market is expected to grow from 37.27 billion yuan in 2015 to 60.32 billion yuan in 2024, reaching 62.6 billion yuan by 2025 [1][4]. Group 1: Industry Definition and Extraction Process - Plant alkaloids are nitrogen-containing organic compounds primarily found in plants, often existing as salts with organic acids. They are predominantly located in the roots, stems, leaves, and fruits of higher plants, especially in dicotyledons [2][3]. - The extraction methods for plant alkaloids include reflux extraction, ultrasonic-assisted extraction, and supercritical fluid extraction, with advancements in technology leading to the discovery of more alkaloids and their physiological activities [3]. Group 2: Current Industry Status - The plant alkaloid market is gaining attention due to its wide availability and excellent properties such as antioxidant, anti-tumor, and anti-inflammatory activities. The market is projected to grow steadily, with significant applications in healthcare and animal husbandry [4]. - The core product, paclitaxel, is experiencing a trend of increasing sales but decreasing prices, with new formulations being adopted rapidly. Key players in the market include Jiangsu Hengrui Medicine and Shijiazhuang Yiling Pharmaceutical [4]. Group 3: Industry Chain - The upstream of the plant alkaloid industry chain includes natural plant resources, with various plant families providing different alkaloids. The midstream involves extraction, processing, and formulation development, while the downstream focuses on applications in pharmaceuticals and health products [5]. Group 4: Development Environment and Policies - The biopharmaceutical industry is a key area for national strategic development, with policies introduced to promote high-quality growth in the pharmaceutical sector. The government is focusing on innovative drug development and improving clinical evaluation and approval processes [6]. Group 5: Competitive Landscape - Major companies in the plant alkaloid sector include Nanjing Green Leaf Pharmaceutical, Jiangsu Hengrui Medicine, and Shijiazhuang Yiling Pharmaceutical, among others. These companies are involved in the development and production of various alkaloid-based drugs [5][7]. Group 6: Industry Development Trends - The plant alkaloid industry is undergoing a transformation driven by technological innovation and market changes, with trends towards upgrading technology, green practices, and precision medicine. The demand for effective and accessible plant alkaloid drugs is rapidly increasing in emerging markets [12][13].

Group 1 - The company, Aosaikang (002755), reported that as of September 20, the number of its shareholders reached 20,047 [1]